



Thomas Cueni

Chair, AMR Industry Alliance

“The AMR Industry Alliance is quite remarkable as it breaks down silos, bringing together big pharma/biotech, generic companies and diagnostics united against superbugs. Ensuring access to antibiotics and diagnostics as well as promoting appropriate use is top of our agenda. The diversity of the members of the Alliance allows us to formulate solutions to address the different challenges across the continuum of care (from prevention, surveillance, screening, to treatment)”

WWW.AMRINDUSTRYALLIANCE.ORG





Thomas Cueni

Director General, IFPMA

"In the battle against AMR, public-private partnerships have a key role in basic research and early development. However, by and large new antibiotic will have to be developed by biotech and pharma companies. At present, there is no sustainable business model for antibiotics. Thus, we urgently need sustainable incentives to encourage investment in antimicrobial R&D"

WWW.AMRINDUSTRYALLIANCE.ORG





James C. Greenwood

President and CEO, BIO

“Effectively addressing the looming crisis of antimicrobial resistance will require not only systemic changes to better incentivize innovation, but also improved stewardship and appropriate use of existing antimicrobials to slow the development of resistant pathogens. World Antibiotic Awareness Week is an excellent opportunity to become better educated on antimicrobial resistance and the responsible use of our antimicrobial arsenal.”

WWW.AMRINDUSTRYALLIANCE.ORG





Andrew Fish

Executive Director, AdvaMedDy

WWW.AMRINDUSTRYALLIANCE.ORG

“TBC”





Adrian van den Hoven

Director General, Medicines for Europe

“TBC”

WWW.AMRINDUSTRYALLIANCE.ORG

